Cibus Reports Third Quarter Financial Results and Provides Year-to-Date Business Update for 2025 GlobeNewswire November 13, 2025 With the addition of Centro Internacional de Agricultura Tropical (CIAT) in the quarter, Cibus now has 5 LATAM Rice customers as momentum continues toward achieving 2027 targeted initial LATAM Rice revenue On track to deliver HT traits to […]

ORIC(R) Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety GlobeNewswire November 13, 2025 Efficacy data remain consistent with prior disclosure and continue to demonstrate broad and deep PSA responses, with 55% PSA50 response rate and 20% PSA90 response rate Rapid and

First Watch Restaurant Group, Inc. to Participate at the Stephens Annual Investment Conference on November 18-19, 2025 GlobeNewswire November 13, 2025 BRADENTON, Fla., Nov. 13, 2025 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc., (Nasdaq: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced that it

Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY(R) Cell-Impermeable Endoprosthesis GlobeNewswire November 13, 2025 SOUTH JORDAN, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the U.S. Centers for Medicare & Medicaid Services (“CMS”) has notified Merit that

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress GlobeNewswire November 13, 2025 Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approval Company is in advanced stages to finalize a strategic

Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis GlobeNewswire November 13, 2025 100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response

SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire November 13, 2025 Business highlights include: Three new top-rated children's hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI) Commercial use of QUELIMMUNE therapy demonstrates positive survival results as reported from the QUELIMMUNE SAVE Surveillance Registry New clinical sites added

Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results GlobeNewswire November 13, 2025 Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment of approximately 5,400 participants in COVID-19 Phase 2b trial with topline

Expion360 Reports Third Quarter 2025 Financial and Operational Results GlobeNewswire November 13, 2025 Q3 2025 Sales Growth of 72% to $2.4 Million Driven by Continued Demand for Battery Products, Accessories and Technologies New CEO to Drive Next Phase of Growth and Expansion REDMOND, Ore., Nov. 13, 2025 (GLOBE NEWSWIRE) — Expion360 Inc. (Nasdaq: XPON) (“Expion360”

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025 GlobeNewswire November 13, 2025 PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy